SEARCH

SEARCH BY CITATION

References

  • 1
    Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999; 94: 1848-1854.
  • 2
    Damnle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94: 1840-1847.
  • 3
    Di Giovanni S, Valentini G, Carducci P, et al. Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. Acta Hematol. 1989; 81: 181-185.
  • 4
    Crespo M, Bosh F, Villamor N, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and dinstinct gene expression profile. Blood. 2003; 348: 1764-1775.
  • 5
    Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004; 351: 893-901.
  • 6
    Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005; 23: 2971-2979.
  • 7
    Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol. 2006; 24: 2337-2342.
  • 8
    Wendtner CM, Ritgen M, Schweighofer CD, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission–experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004; 18: 1093-1101.
  • 9
    Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood. 2008; 111: 5446-5456.
  • 10
    Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002; 43: 1755-1762.
  • 11
    Tam CS, O'Brien S, Lerner S, et al. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma. 2007; 48: 1931-1939.
  • 12
    Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia. Br J Haematol. 2002; 119: 976-984.
  • 13
    Kowal M, Domoszynska A, Lewandoski K, et al. Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukemia (B-CLL)-Polish multicentre study. Leuk Lymphoma. 2004; 45: 1159-1165.
  • 14
    Hendry L, Bowen A, Matutes E, Swansburry J, Catovsky D. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma. Leuk Lymphoma. 2004; 45: 945-950.
  • 15
    Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 2001; 17: 3580-3589.
  • 16
    O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001; 19: 1414-1420.
  • 17
    Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005; 18: 1-9.
  • 18
    Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukemia-updated results of the multicentre study of 378 patients. Br J Haematol. 2000; 108: 357-368.
  • 19
    Weiss MA, Maslak PG, Jurcic JG, et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol. 2003; 43: 1755-1762.
  • 20
    Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006; 24: 1575-1581.
  • 21
    Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer. 2007; 109: 2291-2298.
  • 22
    Wierda W, O'Brien S, Faderl S, et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) an active regimen for heavily treated patients with CLL. Blood. 2006; 108: 31a.
  • 23
    Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003; 101: 3413-3415.
  • 24
    Faderl S, Keating MJ, Do K-A, et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2002; 16: 1045-1052.
  • 25
    O'Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2007; 25: 1114-1120.
  • 26
    O'Brien S, Moore J, Ding L, et al. Addition of oblimersen (Bcl-2 antisense) to fludarabine/cyclophosphamide for relapsed/refractory chronic lymphocytic leukemia extends survival in patients who achieve CR/nPR: results from a randomized phase 3 study [abstract]. Blood. 2007; 110: 231a. Abstract 751.
  • 27
    Bellosillo B, Colomer D, Pons G, Gil J. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998; 100: 142-146.
  • 28
    Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia. Br J Haematol. 2002; 119: 976-984.
  • 29
    Mauro FR, Foa R, Meloni G, et al. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. Haematologica. 2002; 87: 926-933.
  • 30
    Rawstron AC, Kennedy B, Evans P, et al. Quantification of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 2001; 98: 29-35.
  • 31
    Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood. 2002; 99: 2245-2247.
  • 32
    Elter T, Bochmann P, Shultz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol. 2005; 23: 7024-7031.
  • 33
    Tsimberidou A, Wierda WG, Plunkett W, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome of fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008; 26: 196-203.
  • 34
    Osteborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997; 15: 1567-1574.
  • 35
    Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002; 99: 3554-3561.
  • 36
    Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002; 20: 3891-3897.
  • 37
    Ferrajoli A, O'Brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003; 98: 773-778.
  • 38
    Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab (Campath) in fludarabine-refractory CLL: final results of the CLL2h trial GCLLSG and comprehensive analysis of prognostic markers. Blood. 2008; 112: 329a.
  • 39
    Cortelezzi A, Pasquini MC, Sarina B, et al. A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with chemotherapy-refractory chronic lymphocytic leukemia. Haematologica. 2005; 90: 410-412.
  • 40
    Osuji NC, Del Giudice I, Matutes E, Wotherspoon AC, Dearder C, Catovsky D. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica. 2005; 90: 1435-1436.
  • 41
    Nabhan C, Patton D, Gordon LI, et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2004; 45: 2269-2273.
  • 42
    Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004; 103: 3278-3281.
  • 43
    O'Brien S, Ravandi F, Riehl T, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008; 111: 1816-1819.
  • 44
    McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of a patients respond to a 4-dose treatment program. J Clin Oncol. 1998; 16: 2825-2833.
  • 45
    Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001; 98: 1326-1331.
  • 46
    Itala M, Geisler CH, Kimby E, et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicenter study. Eur J Haematol. 2001; 69: 129-134.
  • 47
    Winkler U, Jensen M, Manzke O, et al. Cytokine release sydrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with the anti-CD20 monoclonal antibody. Blood. 1999; 94: 2217-2224.
  • 48
    Castro JE, Sandoval-Sus JD, Bole J, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia. 2008; 22: 2048-2053.
  • 49
    Bowen DA, Call TG, Jenkins GD, et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma. 2007; 48: 2412-2417.
  • 50
    Dungarwalla M, Evans SO, Riley U, et al. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica. 2008; 93: 475-476.
  • 51
    Byrd JC, O'Brien S, Flinn IW, et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007; 13: 4448-4455.
  • 52
    Byrd JC, Castro J, O'Brien S, et al. Comparison of results from a phase 1/2 study of lumiliximab (anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR results. Blood. 2006; 108: 32a.
  • 53
    Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008; 111: 1094-1100.
  • 54
    Osteborg A, Kipps TJ, Mayer J, et al. Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: results from the planned interim analysis of an international pivotal trial. Blood. 2008; 112: 328a.
  • 55
    Koppler H, Heymanns J, Pandorf A, et al. Bendamustine plus mitoxantrone—a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study. Leuk Lymphoma. 2004; 45: 911-913.
  • 56
    Kath R, Blumenstengel K, Fricke HJ, Hoffken K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol. 2001; 127: 48-54.
  • 57
    Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol. 2002; 128: 603-609.
  • 58
    Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica. 2005; 90: 1357-1364.
  • 59
    Weide R, Pandorf A, Heymanns J, et al. Bendamustine/mitoxantrone/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma. 2004; 45: 2445-2449.
  • 60
    Phelps MA, Lin TS, Johnson AJ, et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood. 2009; 113: 2637-2645.
  • 61
    List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodisplastic syndromes. N Engl J Med. 2005; 352: 549-557.
  • 62
    Barlogie B. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. Semin Hematol. 2003; 40: 33-38.
  • 63
    Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002; 100: 3063-3067.
  • 64
    Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008; 118: 2427-2437.
  • 65
    Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed of refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006; 24: 5343-5349.
  • 66
    Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008; 111: 5291-5297.
  • 67
    Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008; 26: 2519-2525.
  • 68
    Pavletic SZ, Khouri IF, Haagenson M, et al. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the center for international blood and marrow transplant research. J Clin Oncol. 2005; 23: 5788-5794.
  • 69
    Dreger P, Brand R, Hansz J, et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia. 2003; 107: 1724-1730.
  • 70
    Rigten M, Stilgenbauer S, von Neuhoff N, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain genes status: implications of minimal residual disease measurement with quantitative PCR. Blood. 2004; 104: 2600-2602.
  • 71
    Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced intensity conditioning and allogeneic stem cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol. 2003; 21: 2747-2753.
  • 72
    Dreger P, Brand R, Milligan D, et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia. 2005; 19: 1029-1033.
  • 73
    Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008; 26: 4912-4920.
  • 74
    Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab in immunomodulation and survival. Exp Hematol. 2004; 32: 28-35.
  • 75
    Dreger P, Corradini P, Kimby E, et al. Indication for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007; 21: 12-17.
  • 76
    Moreno C, Villamor N, Colomer D, et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood. 2006; 107: 4563-4569.